Remicade® (infliximab): 20 years of contributions to science and medicine
R Melsheimer, A Geldhof, I Apaolaza… - Biologics: Targets and …, 2019 - Taylor & Francis
Abstract On August 24, 1998, Remicade®(infliximab), the first tumor necrosis factor-α (TNF)
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
inhibitor, received its initial marketing approval from the US Food and Drug Administration …
Early disease intervention with guselkumab in psoriasis leads to a higher rate of stable complete skin clearance ('clinical super response'): Week 28 results from the …
K Schäkel, K Reich, K Asadullah… - Journal of the …, 2023 - Wiley Online Library
Background Guselkumab is an interleukin (IL)‐23 inhibitor with demonstrated efficacy in
patients with psoriasis. Objectives Evaluate the impact of early disease intervention on …
patients with psoriasis. Objectives Evaluate the impact of early disease intervention on …
IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study …
K Eyerich, P Weisenseel, A Pinter, K Schäkel… - BMJ open, 2021 - bmjopen.bmj.com
Background Guselkumab is an interleukin (IL)-23 pathway blocker with proven efficacy in
patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may …
patients with moderate-to-severe plaque psoriasis. Early intervention with guselkumab may …
The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV …
Background The journey of patients with skin diseases through healthcare has been
scarcely investigated. Objective To analyse the journey of people with skin diseases in the …
scarcely investigated. Objective To analyse the journey of people with skin diseases in the …
Secukinumab treatment in new‐onset psoriasis: aiming to understand the potential for disease modification–rationale and design of the randomized, multicenter …
Background To date, biological treatments have been assessed in subjects with a long‐term
history of psoriasis and previous failures to systemic and topical therapies. In rheumatoid …
history of psoriasis and previous failures to systemic and topical therapies. In rheumatoid …
A Belgian consensus on the definition of a treat‐to‐target outcome set in psoriasis management
L Grine, M de la Brassinne, PD Ghislain… - Journal of the …, 2020 - Wiley Online Library
Objective Treat‐to‐target (T2T) is an algorithm to reach a predefined outcome. Here, we
define a T2T outcome for moderate‐to‐severe psoriasis vulgaris. Methods Briefly, the study …
define a T2T outcome for moderate‐to‐severe psoriasis vulgaris. Methods Briefly, the study …
[HTML][HTML] The course of mycosis fungoides under cytokine pathway blockers: a multicentre analysis of real-life clinical data
I Amitay-Laish, E Guenova… - Acta Dermato …, 2020 - ncbi.nlm.nih.gov
Literature regarding the effect of biologics on the course of mycosis fungoides (MF) is
scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were …
scarce. This multicentre study analysed retrospective data on 19 patients with MF, who were …
The skin may clear but the arthritis won't disappear: focusing on concomitant and new-onset psoriatic arthritis in a daily practice cohort of psoriasis patients on biologic …
ME van Muijen, TW van Hal… - … : Targets and Therapy, 2020 - Taylor & Francis
Background Previously identified risk factors for psoriatic arthritis (PsA); nail dystrophy and
scalp lesions are highly prevalent in patients with moderate-to-severe psoriasis. Therefore …
scalp lesions are highly prevalent in patients with moderate-to-severe psoriasis. Therefore …
Effectiveness, safety and impact of guselkumab on sexuality and perceived stigmatization in patients with psoriasis in routine clinical practice: Week 28 results from the …
S Gerdes, R Ostendorf, A Süß… - Journal of the …, 2024 - Wiley Online Library
Background G‐EPOSS is a prospective, non‐interventional, German multicentre study of
patients with moderate‐to‐severe plaque psoriasis receiving guselkumab, a therapeutic …
patients with moderate‐to‐severe plaque psoriasis receiving guselkumab, a therapeutic …
Treatment persistence in paediatric and adolescent patients with psoriasis followed into young adulthood. From topical to systemic treatment: a prospective …
FM Bruins, I Bronckers, R Cai… - British Journal of …, 2021 - academic.oup.com
Background Although solely topical treatment often suffices, patients with psoriasis may
require more intensive treatment (phototherapy and/or systemic treatments) to control their …
require more intensive treatment (phototherapy and/or systemic treatments) to control their …